Edit |   |
---|---|
Antigenic Specificity | F10 & F9 activated form, Human (Emicizumab biosimilar) |
Clone | Emicizumab |
Host Species | Recombinant |
Reactive Species | human |
Isotype | IgG4 kappa |
Format | purified |
Size | 1mg, 5mg |
Concentration | 1mg/ml |
Applications | n/a |
Reviews / Ratings | If you have used this antibody, please help fellow researchers by submitting reviews to pAbmAbs and antYbuddY. |
Description | Anti-Human F10 & F9 activated form Recombinant Antibody. Emicizumab (trade name Hemlibra) is a humanized bispecific antibody for the treatment of haemophilia A, developed by Genentech and Chugai (a subsidiary of Roche). A Phase I clinical trial found that it was well tolerated by healthy subjects. |
Immunogen | n/a |
Other Names | Anti-F10 & F9 activated form Recombinant Antibody, Research Grade Emicizumab, Anti-Human F10 & F9 activated form Recombinant Antibody, ACE-910, RG6013, hBS910, Antibody Drug Analogues, Monoclonal Antibody, YR1383, Research Grade Biosimilars, Biosimilar Antibody |
Gene, Accession # | CAS: 1610943-06-0 |
Catalog # | YR1383 |
Price | please inquire |
Order / More Info | F10 & F9 activated form, Human (Emicizumab biosimilar) Antibody from KMD BIOSCIENCE CO. LTD. |
Product Specific References | n/a |